Eli Lilly and Company has significantly deepened its footprint in cutting-edge drug discovery by expanding its strategic partnership and licensing…
Read More
FDA approves expanded indication for Lilly’s Jaypirca
The United States Food and Drug Administration (FDA) has granted an expanded regulatory approval for Eli Lilly and Company’s Jaypirca,…
Read More
Eli Lilly and InnoCare Pharma Forge $3.35bn R&D Partnership to Tackle Oncology and Autoimmune Diseases
Eli Lilly and Company has entered into a sweeping, five-drug research and licensing agreement with China-based biopharmaceutical firm InnoCare Pharma,…
Read More
FDA Approves Eli Lilly’s Once-Weekly Basal Insulin Onswik for Type 2 Diabetes Following Robust Phase III Clinical Trials
The United States Food and Drug Administration has officially granted marketing authorization to Eli Lilly and Company for Onswik, chemically…
Read More
Eli Lilly and Partner QurCan Therapeutics Form Strategic Alliance to Advance Next-Generation Genetic Medicines for Nervous System Disorders
The landscape of genetic medicine took a significant stride forward as pharmaceutical giant Eli Lilly and Company joined forces with…
Read More
Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare
Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…
Read More
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Advertising of Obesity Drugs
The escalating rivalry between pharmaceutical giants Novo Nordisk and Eli Lilly has reached a new legal frontier, with Novo Nordisk…
Read More
BMS claims pharma’s most powerful AI supercomputer. How it stacks up to Lilly’s and Roche’s.
Bristol Myers Squibb (BMS) announced Monday its plans to deploy an NVIDIA DGX SuperPOD, a cutting-edge, prepackaged supercomputing platform designed…
Read More
Eli Lilly Acquires AtaiBeckley for $2.8 Billion, Marking Entry into Psychedelic Therapeutics
In a landmark move that signals a significant shift in pharmaceutical investment, Eli Lilly and Company has announced the acquisition…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
